Answers are grounded in this paper and cite their sources.
Neoadjuvant nivolumab plus platinum-based chemotherapy is standard care for resectable non-small cell lung cancer, but patients who start it and never undergo resection remain poorly characterized. We retrospectively analyzed 211 consecutive patients with clinical stage IB–IIIB disease without EGFR , ALK or ROS1 alterations who started treatment at 28 Turkish Oncology Group centers, following each patient from the first cycle. Most patients (83.9%) had stage III disease; the objective response rate was 84.4%. Resection was performed in 132 patients (62.6%); non-resected patients more often had T4 tumors (39.2% vs 15.9%). Counting non-resected patients as non-responders, pathological complete response was 24.6% and major pathological response (including complete response) 38.9%, comparable with CheckMate 816. Higher programmed death-ligand 1 expression was independently associated with major pathological response (odds ratio 2.13 per category, 95% confidence interval 1.09–4.17), whereas worsening radiological response was the only independent correlate of non-resection. Of non-resected patients, 57.0% received thoracic radiotherapy, mostly chemoradiotherapy. Immune-related adverse events occurred in 17.5% (grade 3–4, 3.8%). At a median follow-up of 15.9 months, 24-month event-free and overall survival were 63.2% and 80.0%. Pathological activity was preserved in routine practice, but more than one third of patients never reached surgery.
No takes yet. Share an insight, caveat, or question.
Sünger et al. (2026) studied this question.